Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy - Report - MDSpire
Advertisement
Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy
Clinical Report: Developing and Validating a Clinical Prediction Model for Early Identification of Heart Failure Risk in Asymptomatic Patients with Type 2 Diabetes
Overview
This study developed and validated a clinical prediction model to identify asymptomatic patients with type 2 diabetes at risk for heart failure. The model incorporates various clinical and echocardiographic predictors.
Background
Type 2 diabetes mellitus (T2DM) is a prevalent chronic disease associated with an increased risk of heart failure (HF). The identification of asymptomatic patients at risk for HF is crucial for early intervention and management. This study addresses the need for effective risk prediction models in this high-risk population.
Data Highlights
Predictor
Hazard Ratio (HR)
LASr ≤24%
3.58
NT-proBNP ≥120 pg/mL
2.48
Galectin-3 ≥15 ng/mL
1.79
Age ≥70 years
-
Diabetes duration ≥12 years
-
BMI ≥30 kg/m²
-
UACR ≥60 mg/g
-
Key Findings
The model identified independent predictors of heart failure risk, including LASr, NT-proBNP, and galectin-3.
Patients were stratified into low, intermediate, and high-risk groups based on a scoring system.
24-month cumulative incidences of heart failure were 4.2% for low risk, 11.7% for intermediate risk, and 27.5% for high risk.
The model demonstrated a C-statistic of 0.835, indicating good discrimination.
Incorporating LASr and galectin-3 improved the model's predictive ability.
Clinical Implications
External validation is necessary before routine clinical application of the developed model.
Conclusion
This study presents a validated prediction model for heart failure risk in asymptomatic T2DM patients, highlighting the importance of integrating clinical and echocardiographic data for risk stratification.
